Drugs / BM-3103
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05062070 Comparator | May 2022 → Jun 2023 | epidermolysis bullosa simplex 1A, generalized severe | BioMendics, LLC | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BM-3103 | “Active Ingredient BM-3103” NCT05062070 ↗ |